You are here
HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.
Title | HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa. |
Publication Type | Journal Article |
Year of Publication | 2011 |
Authors | Gottlieb, GS, Smith, RA, Badiane, NMery Dia, Ba, S, Hawes, SE, Toure, M, Starling, AK, Traore, F, Sall, F, Cherne, SL, Stern, J, Wong, KG, Lu, P, Kim, M, Raugi, DN, Lam, A, Mullins, JI, Kiviat, NB |
Corporate Authors | Papa Salif Sow for the UW-Dakar HIV-2 Study Group |
Journal | PLoS One |
Volume | 6 |
Issue | 7 |
Pagination | e22204 |
Date Published | 2011 |
ISSN | 1932-6203 |
Keywords | Adult, Base Sequence, Drug Resistance, Viral, Female, Genetic Variation, HIV Integrase, HIV Integrase Inhibitors, HIV-2, Humans, Male, Middle Aged, Molecular Sequence Data, Phylogeny, Senegal, Young Adult |
Abstract | BACKGROUND: Antiretroviral therapy for HIV-2 infection is hampered by intrinsic resistance to many of the drugs used to treat HIV-1. Limited studies suggest that the integrase inhibitors (INIs) raltegravir and elvitegravir have potent activity against HIV-2 in culture and in infected patients. There is a paucity of data on genotypic variation in HIV-2 integrase that might confer intrinsic or transmitted INI resistance. METHODS: We PCR amplified and analyzed 122 HIV-2 integrase consensus sequences from 39 HIV-2-infected, INI-naive adults in Senegal, West Africa. We assessed genetic variation and canonical mutations known to confer INI-resistance in HIV-1. RESULTS: No amino acid-altering mutations were detected at sites known to be pivotal for INI resistance in HIV-1 (integrase positions 143, 148 and 155). Polymorphisms at several other HIV-1 INI resistance-associated sites were detected at positions 72, 95, 125, 154, 165, 201, 203, and 263 of the HIV-2 integrase protein. CONCLUSION: Emerging genotypic and phenotypic data suggest that HIV-2 is susceptible to the new class of HIV integrase inhibitors. We hypothesize that intrinsic HIV-2 integrase variation at "secondary" HIV-1 INI-resistance sites may affect the genetic barrier to HIV-2 INI resistance. Further studies will be needed to assess INI efficacy as part of combination antiretroviral therapy in HIV-2-infected patients. |
DOI | 10.1371/journal.pone.0022204 |
Alternate Journal | PLoS ONE |
PubMed ID | 21765953 |